Ongoing pain despite aggressive opioid pain management among persons with HIV

Clinical Journal of Pain

Volumn 26, Issue 3, 2010, Pages 190-198

  Koeppe, John ^a   Armon, Carl ^b   Lyda, Karen ^c   Nielsen, Craig ^a   Johnson, Steven ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CENTRAL STIMULANT AGENT; DRONABINOL; FENTANYL; MOOD STABILIZER; NEUROLEPTIC AGENT; OPIATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SELF REPORT;

EID: 77249171299     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181b91624     Document Type: Article

References (55)

1. Douaihy AB Stowell KR Kohnen S et al. Psychiatric aspects of comorbid HIV/AIDS and pain Part 2. AIDS Reader. 2007, 17:350-352.
2. Larue F, Fontaine A, Colleau SM. Underestimation and under-treatment of pain in HIV disease: multicentre study. BMJ. 1997;314:23-28. (Pubitemid 27023232)
3. Dobalian A, Tsao JC, Duncan RP. Pain and the use of outpatient services among persons with HIV: results from a nationally representative survey. Med Care. 2004;42:129-138.
4. Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006;66:1679-1687.
5. Schifitto G, McDermott MP, McArthur JC, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology. 2005;64:842-848.
6. Lichtenstein KA, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis. 2005;40:148-157.
7. Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology. 2006;66:867-873.
8. Joly V, Flandre P, Meiffredy V, et al. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). Antimicrobial Agents Chemother. 2002;46:1906-1913.
9. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. New Engl J Med. 2003;349:2304-2315.
10. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV brain bank. Arch Neurol. 2004;61:546-551.
11. Harkness EF, Macfarlane GJ, Nahit ES, et al. Risk factors for new-onset low back pain amongst cohorts of newly employed workers. Rheumatology. 2003;42:959-968.
12. Harkness EF, Macfarlane GJ, Nahit E, et al. Mechanical injury and psychosocial factors in the work place predict the onset of widespread body pain: a two-year prospective study among cohorts of newly employed workers. Arthritis Rheumat. 2004;50:1655-1664.
13. Callahan LF, Smith WJ, Pincus T. Self-report questionnaires in five rheumatic diseases: comparisons of health status constructs and associations with formal education level. Arthritis Care & Research. 1989;2:122-131.
14. Papageorgiou AC, Macfarlane GJ, Thomas E, et al. Psycho-social factors in the workplace-do they predict new episodes of low back pain? Evidence from the south manchester back pain study. Spine. 1997;22:1137-1142.
15. Jones GT, Harkness EF, Nahit ES, et al. Predicting the onset of knee pain: results from a 2-year prospective study of new workers. Annals of the Rheumatic Diseases. 2007;66:400-406.
16. Krueger AB, Stone AA. Assessment of pain: a community-based diary survey in the USA. Lancet. 2008;371:1519-1525.
17. Tsao JC, Dobalian A, Stein JA. Illness burden mediates the relationship between pain and illicit drug use in persons living with HIV. Pain. 2005;119:124-132.
18. Karon JM, Fleming PL, Steketee RW, et al. HIV in the United States at the turn of the century: an epidemic in transition. American Journal of Public Health. 2001;91:1060-1068.
19. McQuillan GM, Kruszon-Moran D, Kottiri BJ, et al. Prevalence of HIV in the US household population: the national health and nutrition examination surveys, 1988 to 2002. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2006;41:651-656.
20. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515-521.
21. Estanislao L, Carter K, et al, Lidoderm-HIV Neuropathy Group. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2004;37: 1584-1586.
22. Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Journal of Neurology. 2004;251:1260-1266.
23. Rabing CE, Stegger M, Jensen-Fangel S, et al. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clinical Infectious Diseases. 2004;39:1371-1379.
24. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60:1508-1514.
25. Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115-2119.
26. McArthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology. 2000;54:1080-1088.
27. Paice JA, Ferrans CE, Lashley FR, et al. Topical capsaicin in the management of HIV-associated peripheral neuropathy. Journal of Pain & Symptom Management. 2000;19:45-52.
28. Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology. 1998;51:1682-1688.
29. Kaiser JD, Campa AM, Ondercin JP, et al. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2006;42:523-528.
30. Schifitto G, Yiannoutsos CT, Simpson DM, et al. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. Journal of Neurovirology. 2006;12:328-331.
31. Kemper CA, Kent G, Burton S, et al. Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirol-ogy. 1998;19:367-372.
32. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1998;280: 1590-1595.
33. Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology. 1996;47:1254-1259.
34. Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain. 2006;10:667-676.
35. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007; 146:116-127.
36. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174:1589-1594.
37. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008;24:469-478.
38. Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS. 1996; 10:1033-1039.
39. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain. 2006;7:43-48.
40. Passik SD, Kirsh KL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psycho-pharmacol. 2008;16:400-404.
41. Sullivan MD, Edlund MJ, Zhang L, et al. Association between mental health disorders, problem drug use, and regular prescription opioid use. Archi Intern Med. 2006;166:2087-2093.
42. Wasan AD, Wootton J, Jamison RN. Dealing with difficult patients in your pain practice. Reg Anesth Pain Med. 2005; 30:184-192.
43. Solomon DH, Avorn J, Wang PS, et al. Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum. 2006;55:35-41.
44. Hermos JA, Young MM, Gagnon DR, et al. Characterizations of long-term oxycodone/acetaminophen prescriptions in veteran patients. Arch Intern Med. 2004;164:2361-2366.
45. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25:171-186.
46. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479-496
47. Toomey TC, Mann JD, Abashian SW, et al. Pain locus of control scores in chronic pain patients and medical clinic patients with and without pain. Clin J Pain. 1993;9:242-247.
48. Carson JW, Keefe FJ, Affleck G, et al. A comparison of conventional pain coping skills training and pain coping skills training with a maintenance training component: a daily diary analysis of short-and long-term treatment effects. J Pain. 2006;7:615-625.
49. Zautra AJ, Davis MC, Reich JW, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol. 2008;76:408-421.
50. Martin PR, Forsyth MR, Reece J. Cognitive-behavioral therapy versus temporal pulse amplitude biofeedback training for recurrent headache. Behav Ther. 2007;38:350-363. Epub 2007 Sep 27.
51. Spinhoven P, Ter Kuile M, Kole-Snijders AM, et al. Catastrophizing and internal pain control as mediators of outcome in the multidisciplinary treatment of chronic low back pain. Eur J Pain. 2004;8:211-219.
52. Haugli L, Steen E, Laerum E, et al. Learning to have less pain-is it possible? A one-year follow-up study of the effects of a personal construct group learning programme on patients with chronic musculoskeletal pain. Patient Educ Couns. 2001;45: 111-118.
53. Johansson C, Dahl J, Jannert M, et al. Effects of a cognitive-behavioral pain-management program. Behav Res Ther. 1998; 36:915-930.
54. Spence SH. Cognitive-behaviour therapy in the treatment of chronic, occupational pain of the upper limbs: a 2 years follow-up. Behav Res Ther. 1991;29:503-509.
55. Cherny N. The treatment of neuropathic pain: from hubris to humility. Pain. 2007;132:225-226.